News - Generics, Cipla

Filter

Current filters:

GenericsCipla

Popular Filters

Cipla to invest £100 million in its UK subsidiary

Cipla to invest £100 million in its UK subsidiary

07-07-2014

Indian drugmaker Cipla has decided to make a significant investment in its UK subsidiary over the next…

CiplaFinancialGenericsMarkets & MarketingResearchUK

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

30-06-2014

Cipla has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin…

ActoriseAmgenAranespBiosimilarsCiplaGenericsHeteroIndiaMarkets & MarketingMergers & AcquisitionsOncologyRest of the World

India/USA trade dispute could impact AIDS treatment programs

10-03-2014

The trade dispute over intellectual property rights between the USA and India is set to derail the distribution…

Anti-viralsCiplaGenericsGilead SciencesGlaxoSmithKlineIndiaPatentsPricingUSA

Leading Indian drugmakers eye pharma production in Russia

08-07-2013

Several top Indian drugmakers and suppliers, including Dr Reddy's (NYSE: RDY), Ranbaxy (BSE: 500359),…

Asia-PacificAurobindo PharmaCiplaDr Reddy's LaboratoriesEuropeGenericsProductionRanbaxy Laboratories

India's Cipla ups bid for Cipla Medpro now seeking 100% control for around $512 million

01-03-2013

Indian drugmaker Cipla (BSE: 500087) has made an offer to the shareholders of Cipla Medpro South Africa…

CiplaCipla MedproGenericsMarkets & MarketingPharmaceutical

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Impax in deal with Perrigo; Cipla eyes South Africa acquisition

22-11-2012

Impax Laboratories (Nasdaq: IPXL) said yesterday that it plans to collaborate with fellow US drugmaker…

CiplaCipla MedproGenericsImpax LaboratoriesMarkets & MarketingMergers & AcquisitionsNorth AmericaPerrigoResearchRest of the World

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination

24-07-2012

Coinciding with the XIX International AIDS Conference in Washington DC, the Drugs for Neglected Diseases…

Anti-viralsCiplaGenericsGlobalPharmaceuticalResearch

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Back to top